|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Parkinsons Disease - Evidence of neuroprotection essential to progress treatment dynamics
Datamonitor, Dec 2007, Pages: 260
Parkinsons disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the seven major markets (7MM); with patients typically being diagnosed in their early sixties and living for over 18 years after the onset of first symptoms.
Scope
- Overview of epidemiology, presentation, and diagnostic assessment in PD
- Breakdown of first-line treatment regimens for early-, mid-, and advanced-stage disease, with analysis of second-line add-on and switching dynamics
- Influences on neurologists treatment decisions and their perception of current brands
- Evaluation of treatment outcomes and surgical procedures for PD
Highlights of this title
Neurologists indicated that the DAs Mirapex (pramipexole) and Requip (ropinirole) are generally the initial treatment of choice for younger presenting patients. While levodopa is reserved for patients over 65 years of age, neurologists may prescribe the MAOIs selegiline and rasagiline (Azilect) in young patients with only mild symptoms at onset.
Neurologists indicated that only 36% of advanced-stage PD patients are adequately controlled by pharmacological therapy. Considering the even distribution of patient severities (30% early-stage, 39% mid-stage and 31% advanced-stage), the advanced-stage patient group is particularly poorly served by current therapies.
Neurologists estimated that approximately 9% of all PD patients will eventually require surgery. Deep Brain Stimulation is by far the most common surgical procedure used in the 7MM and neurologists indicated that over 70% of patients receiving it experience both a reduction in PD symptoms and a reduction in the dose of pharmacological medication.
Key reasons to purchase this title
- Target prescribers more effectively, through an understanding of prescribing behavior and its influences
- Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
- Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
Customers who bought this item also bought
Stakeholder Insight: Parkinsons Disease - Evidence of neuroprotection essential to progress treatment dynamics
Large Pharma: 2004 A Year Of Progress
Prostate and Breast Cancer- New Treatments & Developmental Progress
Progress in RNA-Based Therapeutics
Premium Company Profile Progress Energy, Inc.
Service Line Protection: Energy Service Providers Move Beyond Pipes and Wires to Offer Peace of Mind
Launching 3G: Progress and Bright Prospects for WCDMA
Services Oriented Architecture (SOA) Engine Market Opportunities, Strategies, and Forecasts, 2007 to 2013
|
|
|
|
